 |
|
An Open Study to Assess the Efficacy and Safety of Topical 3% Diclofenac in a 2.5% Hyaluronic Acid Gel for the Treatment of Actinic Keratoses
Jason K. Rivers, MD, FRCPC;
David I. McLean, MD, FRCPC
Arch Dermatol. 1997;133(10):1239-1242.
Abstract
| |
Background
Actinic keratoses are potential precursors of invasive squamous cell carcinoma; therefore, treatment is often recommended. Current topical treatments may cause considerable discomfort, pain, or skin irritation. This study was established to explore the role, if any, of topical 3% diclofenac in 2.5% hyaluronic acid gel in the management of actinic keratoses.
Observations
An open-label study was conducted of topical 3% diclofenac in 2.5% hyaluronic acid gel applied to 1 or more actinic keratoses. Patients were instructed to apply 1.0 g of the gel twice daily for as many as 180 days. Treatment was stopped earlier than 180 days if lesions were assessed as cleared. Twenty-nine adults were treated for periods of 33 to 176 days (median, 62 days). Of the 29 subjects, 27 were reevaluated 30 days after drug therapy discontinuation. Of the 27 patients, 22 (81%) had a complete response and another 4 (15%) showed marked clinical improvement. The preparation was generally well tolerated, although in 7 patients (24%) an irritant-type contact dermatitis developed, which was confined to the treatment site.
Conclusion
Topical 3% diclofenac in 2.5% hyaluronic acid gel may be a clinically useful topical agent for the treatment of actinic keratoses.
Arch Dermatol. 1997;133:1239-1242
Author Affiliations
From the Division of Dermatology, University of British Columbia and Vancouver Hospital and Health Sciences Centre, Vancouver.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Trial of Short Incubation, Broad-Area Photodynamic Therapy for Facial Actinic Keratoses and Diffuse Photodamage
Touma et al.
Arch Dermatol 2004;140:33-40.
ABSTRACT
| FULL TEXT
|
